FI952458A7 - Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-anta gonisteina - Google Patents

Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-anta gonisteina Download PDF

Info

Publication number
FI952458A7
FI952458A7 FI952458A FI952458A FI952458A7 FI 952458 A7 FI952458 A7 FI 952458A7 FI 952458 A FI952458 A FI 952458A FI 952458 A FI952458 A FI 952458A FI 952458 A7 FI952458 A7 FI 952458A7
Authority
FI
Finland
Prior art keywords
dimethylbenzopyrans
dimethylbenzofurans
antagonists
Prior art date
Application number
FI952458A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI952458L (fi
FI952458A0 (fi
Inventor
Laerhoven Willy Joannes Carolus Van
Daele Georges Henri Paul Van
Jean-Paul Rene Marie Andre Bosmans
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI952458L publication Critical patent/FI952458L/fi
Publication of FI952458A7 publication Critical patent/FI952458A7/fi
Publication of FI952458A0 publication Critical patent/FI952458A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI952458A 1992-11-20 1993-11-15 Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-antagonisteina FI952458A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20
PCT/EP1993/003206 WO1994012494A1 (en) 1992-11-20 1993-11-15 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Publications (3)

Publication Number Publication Date
FI952458L FI952458L (fi) 1995-05-19
FI952458A7 true FI952458A7 (fi) 1995-05-19
FI952458A0 FI952458A0 (fi) 1995-05-19

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952458A FI952458A0 (fi) 1992-11-20 1993-11-15 Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-antagonisteina

Country Status (31)

Country Link
US (2) US5674868A (enExample)
EP (1) EP0669919B1 (enExample)
JP (1) JP2830952B2 (enExample)
KR (1) KR0166661B1 (enExample)
AT (1) ATE176232T1 (enExample)
AU (1) AU680640B2 (enExample)
BG (1) BG62489B1 (enExample)
BR (1) BR9307477A (enExample)
CA (1) CA2149044C (enExample)
CZ (1) CZ287262B6 (enExample)
DE (1) DE69323322T2 (enExample)
DK (1) DK0669919T3 (enExample)
ES (1) ES2129615T3 (enExample)
FI (1) FI952458A0 (enExample)
GR (1) GR3029831T3 (enExample)
HU (2) HUT72740A (enExample)
IL (3) IL119273A0 (enExample)
LV (1) LV10956B (enExample)
MX (1) MX9307257A (enExample)
NO (2) NO307690B1 (enExample)
NZ (1) NZ257854A (enExample)
OA (1) OA10158A (enExample)
PL (1) PL176051B1 (enExample)
RO (1) RO115160B1 (enExample)
RU (1) RU2116072C1 (enExample)
SG (1) SG47488A1 (enExample)
SK (1) SK282378B6 (enExample)
TW (1) TW294595B (enExample)
UA (1) UA49792C2 (enExample)
WO (1) WO1994012494A1 (enExample)
ZA (1) ZA938676B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0975327B1 (en) 1997-04-18 2003-07-02 Janssen Pharmaceutica N.V. Use of 5ht3 antagonists for promoting intestinal lavage
KR100358374B1 (ko) * 1997-07-11 2002-10-25 얀센 파마슈티카 엔.브이. 5-ｈｔ3 및 5-ｈｔ4 매개된 질환에 유용한(+)-노르시사프라이드
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
ES2551027T3 (es) 2003-11-20 2015-11-13 Janssen Pharmaceutica Nv 2-Quinolinonas 7-fenilalquil sustituidas y 2-quinoxalinonas como inhibidores de poli(ADP-ribosa) polimerasa
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
ES2563954T3 (es) 2004-06-30 2016-03-16 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de PARP
KR101286969B1 (ko) 2004-06-30 2013-07-23 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 퀴나졸리논 유도체
CN1980913B (zh) 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
SI2134691T1 (sl) 2007-03-08 2012-06-29 Janssen Pharmaceutica Nv Derivati kvinolina kot PARP in TANK inhibitorji
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
RU2490260C2 (ru) 2008-03-27 2013-08-20 Янссен Фармацевтика Нв Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина
AU2009228945B2 (en) 2008-03-27 2013-05-02 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4914207A (en) * 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
PL176051B1 (pl) 1999-03-31
MX9307257A (es) 1994-05-31
IL119273A0 (en) 1996-12-05
CZ287262B6 (en) 2000-10-11
US5674868A (en) 1997-10-07
ATE176232T1 (de) 1999-02-15
FI952458L (fi) 1995-05-19
TW294595B (enExample) 1997-01-01
IL107654A0 (en) 1994-02-27
EP0669919B1 (en) 1999-01-27
ZA938676B (en) 1995-05-19
AU5465994A (en) 1994-06-22
KR0166661B1 (ko) 1999-01-15
JP2830952B2 (ja) 1998-12-02
HU9501476D0 (en) 1995-07-28
CZ125895A3 (en) 1995-10-18
BG99593A (en) 1995-12-29
RO115160B1 (ro) 1999-11-30
ES2129615T3 (es) 1999-06-16
NO308530B1 (no) 2000-09-25
NO951980D0 (no) 1995-05-19
IL107654A (en) 1998-01-04
SK67595A3 (en) 1995-11-08
CA2149044A1 (en) 1994-06-09
LV10956A (lv) 1995-12-20
HU211546A9 (en) 1995-12-28
NO995762L (no) 1995-05-19
DK0669919T3 (da) 1999-09-13
BG62489B1 (bg) 1999-12-30
RU95113434A (ru) 1997-03-10
IL119273A (en) 2000-07-16
FI952458A0 (fi) 1995-05-19
GR3029831T3 (en) 1999-06-30
NO995762D0 (no) 1999-11-24
EP0669919A1 (en) 1995-09-06
RU2116072C1 (ru) 1998-07-27
OA10158A (en) 1996-12-18
NZ257854A (en) 1997-04-24
AU680640B2 (en) 1997-08-07
US5863923A (en) 1999-01-26
LV10956B (en) 1996-10-20
NO307690B1 (no) 2000-05-15
PL309045A1 (en) 1995-09-18
JPH08505840A (ja) 1996-06-25
SK282378B6 (sk) 2002-01-07
HUT72740A (en) 1996-05-28
WO1994012494A1 (en) 1994-06-09
BR9307477A (pt) 1999-06-29
UA49792C2 (uk) 2002-10-15
CA2149044C (en) 2007-04-03
DE69323322T2 (de) 1999-09-09
SG47488A1 (en) 1998-04-17
DE69323322D1 (de) 1999-03-11
NO951980L (no) 1995-05-19

Similar Documents

Publication Publication Date Title
FI953666L (fi) Hetersykliset yhdisteet ja niiden valmistus ja käyttö
FI954131L (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
FI945625L (fi) Indolokarbatsoli-imidit ja niiden käyttö
FI945434L (fi) 4-markatpoasetyyliamino/2/bentsatsepinoni (3) johdannaisia ja niiden käyttö enkefalinaasi-inhibiittoreina
FI19992420L (fi) Mikrobifytaasin kloonaus ja ilmentäminen
FI954130A7 (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
DE69406116D1 (de) Reinigungszusammensetzung und verwendungsverfahren
FI904659A7 (fi) Uusia bentsimidatsoliyhdisteitä ja niiden käyttö
FI960353A0 (fi) Ihmisen interleukiini-10:n agonistit ja antagonistit
FI943313L (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
FI935728L (fi) Substituoituja 4-fenyylipyridoneja ja 4-fenyyli-2-alkoksipyridiinejä
FI955430L (fi) Bisyklisiä amidijohdannaisia ja niiden käyttö lihasten jännitystä laukaisevina aineena
FI952458L (fi) Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-antagonisteina
FI943837L (fi) Ksylanaasi B:n kloonaus ja ilmentäminen
FI922905A7 (fi) Imidatsoliyhdisteiden valmistus ja käyttö
FI951992A7 (fi) Uusia substituoituja atsetidinoneja anti-inflammatorisina ja antidegeneratiivisina aineina
FI945427A7 (fi) Dynemisiinianalogien enantiomeerit, niiden valmistus ja käyttö
NO940190D0 (no) Anvendelse av x-ketoglutarat
FI944714L (fi) Beta-karboliinien uusi käyttö
NO931399D0 (no) Anvendelse av naturstein
FI950883L (fi) BAPP-C100-reseptorin kloonaus ja ilmentäminen
FI950515A7 (fi) Isoseriinijohdannaiset ja niiden käyttö leukotrieeniantagonisteina
FI922124A7 (fi) Atsabisykloamideja ja estereitä 5-HT3-reseptorin antagonisteina
IS4109A (is) Notkun handhverfs díhýdrópýridíns
KR920021881U (ko) 최루분사용